N@N

TLH, GBF, BIV, BLV, IBIO Are Seasonally Ripe To Go Down In the Next Five Weeks

December 16, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of iShares Barclays 10-20 Year Treasury Bond Fund (NYSE:TLH), iShares Barclays Government/Credit Bond Fund (NYSE:GBF), Vanguard Intermediate-Term Bond ETF (NYSE:BIV), Vanguard Long-Term Bond ETF (NYSE:BLV), iBio, Inc. (NYSE:IBIO) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

The following stocks are expected to go Down:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  TLH     iShares Barclays 10-20 Year Treasury Bond Fund  -0.93%           100.00% (9 of 9)     Tuesday, December 27th 2016
  GBF     iShares Barclays Government/Credit Bond Fund  -0.42%           88.89% (8 of 9)      Wednesday, December 21st 2016
  BIV     Vanguard Intermediate-Term Bond ETF  -0.93%           88.89% (8 of 9)      Wednesday, December 21st 2016
  BLV     Vanguard Long-Term Bond ETF      -1.17%           88.89% (8 of 9)      Wednesday, December 21st 2016
  IBIO    iBio, Inc.                       -8.80%           87.50% (7 of 8)      Wednesday, December 28th 2016

iShares Barclays 10-20 Year Treasury Bond Fund (NYSE:TLH) - iShares Trust iShare Lehman 1020 Year Treasury Bond Fund.

iShares Barclays Government/Credit Bond Fund (NYSE:GBF) - iShares Trust iShares Lehman Government/Credit Bond Fund.

Vanguard Intermediate-Term Bond ETF (NYSE:BIV) - Vanguard IntermediateTerm Bond ETF.

Vanguard Long-Term Bond ETF (NYSE:BLV) - Vanguard LongTerm Bond ETF.

iBio, Inc. (NYSE:IBIO) - iBio, Inc., a biotechnology company, focuses on commercializing its proprietary plant-based protein expression technologies in the United States and internationally. The company s proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; iBioModulator, a technology platform that is designed to enhance the potency and duration of effect of prophylactic and therapeutic vaccines; and iBio Advanced Technologies. Its therapeutic protein product candidates comprise IBIO-CFB03 for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases; C1 esterase inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement product; and Palivizumab, a monoclonal antibody. The company s vaccine candidates include H1N1 Influenza and H5N1 Influenza viral disease vaccines, which have completed Phase I clinical trials; Yellow Fever viral disease vaccine, which is in preclinical stage; Human Papillomavirus therapeutic vaccine; and malaria and hookworm parasitic pathogen vaccines, which are in Phase I clinical trials. Its biodefense product candidates include Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody. The company has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor. It also has a collaboration and license agreement with FioCruz for the use of its proprietary technology in connection with the development, manufacture, and commercialization of vaccines; and a license and collaboration agreement with Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. iBio, Inc. is based in New York, New York..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---